Despite a risk for severe side effects, pembrolizumab has a record of improving recurrence-free survival that makes it an appealing treatment for advanced melanoma.

From novel pharmaceuticals to telemedicine, most healthcare companies are on a mission to drive better patient outcomes. Despite the rosy long-term prospects, short-term headwinds such as COVID ...

Learn more about whether Alvotech or BioCryst Pharmaceuticals, Inc. is a better investment based on AAII's A+ Investor grades, which compare both companies' key financial metrics.

The report runs an in-depth analysis of market trends, key players, and future opportunities. The generic drugs market ...

The use of RWD data in place of placebo groups is improving various elements across the clinical trial space.

Merck is expanding domestic manufacturing with a $895 million investment in its Kansas factory, one of several major projects ...

“Melanoma New Zealand has been engaging with Pharmac advocating for increased funding for treatments for melanoma patients and providing technical expertise. Today’s announcement is long overdue, and ...

Iovance Biotherapeutics, Inc. IOVA incurred a first-quarter 2025 loss of 36 cents per share, wider than the Zacks Consensus ...

The charity has sold a portion of its royalty interest in Keytruda to a wholly owned European subsidiary of Canada Pension Plan Investment Board (CPPIB) for $1.297 billion.

An evaluation of nearly 19,000 patients with metastatic colorectal cancer supported clinical trial data that immunotherapy ...

AstraZeneca's run of positive trial results with its cancer therapies has continued with a win for its immunotherapy Imfinzi in non-muscle invasive bladder cancer (NMIBC).

Makers of organoids and cell models cheered the decision and said it will bolster the development of precision medicines, ...